Clinicopathologic Features of Retroperitoneal Malignant Solitary Fibrous Tumors.

Crit Rev Eukaryot Gene Expr

Department of Peritoneal Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Published: March 2022

We aimed to explore the clinicopathologic and histologic characteristics, as well as the (differential) diagnosis of retroperitoneal malignant solitary fibrous tumors (RMSFTs) in this study. Nine cases of RMSFTs were recruited and identified by an experienced pathologist from the Pathology Department of Beijing Shijitan Hospital. Clinical information was extracted from medical records and obtained by phone calls. A systematic review of published literature on RMSFTs was conducted using PubMed. A pre-specified search strategy was adopted using the key words "solitary fibrous tumor" and "retroperitoneum." Case reports and literature published in the China Academic Journals (CNKI) and WAN FANG databases were also included. In total, 58 patients (33 males and 25 females) were included; their age ranged from 17 to 83 years, with a median age of 52 years. The tumor size ranged from 4 to 36 cm, and most patients had abdominal masses and pain. Of these patients, 56 underwent surgical resection, and two patients died and underwent an autopsy. All patients were followed up for up to 288 months (with a median follow-up of 36 months). RMSFTs are extremely rare. Their diagnosis mainly relies on the histological morphology and the expression profiles of a panel of pathologic molecules measured by immunohistochemistry. Diagnosis of RMSFTs is usually based on the expression of biomarkers such as vimentin, CD34, Bcl-2, CD99, and STAT6. Differential diagnosis includes spindle-shaped cell tumors, such as schwannoma, gastrointestinal stromal tumors, dermatofibrosarcoma protuberans, synovial sarcoma, malignant peripheral nerve sheath tumors, and fibrosarcoma. RMSFTs are prone to recur and even metastasize. Complete resection remains a major treatment, and close follow-up is highly recommended.

Download full-text PDF

Source
http://dx.doi.org/10.1615/CritRevEukaryotGeneExpr.2021037880DOI Listing

Publication Analysis

Top Keywords

retroperitoneal malignant
8
malignant solitary
8
solitary fibrous
8
fibrous tumors
8
differential diagnosis
8
rmsfts
6
tumors
5
patients
5
clinicopathologic features
4
features retroperitoneal
4

Similar Publications

Clear cell renal cell carcinoma is the predominant subtype of kidney cancer. With distant metastasis, the overall survival rate for patients with renal cell carcinoma decreases significantly compared to localized disease. However, pembrolizumab plus axitinib combination is safe and improves long-term survival.

View Article and Find Full Text PDF

Objectives: Retroperitoneal nerve sheath tumors are uncommon, representing a small fraction of all primary retroperitoneal neoplasms. Accurate differentiation between benign and malignant forms is essential for optimal clinical management. This study assessed the clinical profiles and sonographic traits of retroperitoneal nerve sheath tumors with the goal of enhancing diagnostic precision and developing therapeutic strategies.

View Article and Find Full Text PDF

Introduction And Importance: Appendiceal cancers are rare tumors, with mucinous cystadenocarcinoma accounting for 58 % of malignant appendiceal tumors. Mucinous cystadenocarcinomas are typically low grade but may lead to pseudomyxoma peritonei, causing accumulation of gelatinous material in the abdomen, often referred to as 'jelly belly'. In rare instances, the tumor may perforate into the retroperitoneal cavity leading to the phenomenon described as pseudomyxoma retroperitonei or extraperitonei.

View Article and Find Full Text PDF

Introduction: Local recurrence for upper tract urothelial carcinoma typically occurs within 2 years post-surgery. We report a rare case of retroperitoneal recurrence as squamous cell carcinoma 10 years after nephroureterectomy.

Case Presentation: A 67-year-old female was referred to our urology department for a left ureteral tumor.

View Article and Find Full Text PDF

Durable and deep response to CVD chemotherapy in SDHB-mutated metastatic paraganglioma: case report.

Front Endocrinol (Lausanne)

January 2025

Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Introduction: Succinate dehydrogenase subunit B (SDHB)-mutated paragangliomas (PGLs) are rare neuroendocrine tumors characterized by increased malignancy, readily metastasizing, and poorer prognosis. Here we report a case of SDHB-mutated metastatic PGL, wherein the patient showed significant tumor shrinkage and complete symptom remission following chemotherapy. We aim to contribute additional evidence to the existing knowledge associated with SDHB-mutated PGLs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!